- Delivering Pan India
Cabozanib® (Cabozantinib) 20 mg and 60 mg tablets by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Cabozantinib 20 mg / 60 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | 20 mg: 30 tablets; 60 mg: 30 tablets |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Cabozanib® (Cabozantinib) 20 mg and 60 mg Tablets — Multi-Targeted Kinase Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Cabozanib® is a brand of cabozantinib tablets, an oral kinase inhibitor, marketed by BDR Pharmaceuticals. According to the US prescribing information for the reference product (Cabometyx®), cabozantinib is indicated for advanced renal cell carcinoma (RCC), including first-line use in combination with nivolumab; hepatocellular carcinoma (HCC) previously treated with sorafenib; certain radioiodine-refractory differentiated thyroid cancer; and previously treated pancreatic and extra-pancreatic neuroendocrine tumours in defined patients. Indications for Cabozanib in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe cabozantinib, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Cabozanib® (cabozantinib) 20 mg and 60 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Cabozanib contains cabozantinib, an oral multi-targeted receptor tyrosine kinase inhibitor. Both presentations on this page contain the same active ingredient and differ in strength.
How it works, according to the label: The reference label describes cabozantinib as a small molecule that inhibits multiple receptor tyrosine kinases involved in tumour growth, blood-vessel formation (angiogenesis) and the tumour microenvironment, including MET, VEGF receptors and AXL.
The current US prescribing information for Cabometyx® (cabozantinib tablets; DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Cabozanib pack insert.
The studies below are summarised as published; they describe the evidence for cabozantinib, the active ingredient, and are not a recommendation for any patient.
Cabozanib is a brand of cabozantinib marketed in India; these trials were conducted with the reference product. The approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Cabozantinib 20 mg | Tablets (oral) | 30 tablets |
| Cabozantinib 60 mg | Tablets (oral) | 30 tablets |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology department buyers, and pharmacies that source specialty oral oncology products. Cabozantinib is prescribed and supervised by a physician, as described in the prescribing information.
The US prescribing information for Cabometyx® reports that, in patients treated with cabozantinib and nivolumab, the most common adverse reactions (20% or more) included diarrhoea, fatigue, hepatotoxicity, palmar-plantar erythrodysaesthesia (PPE), stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite and nausea. Warnings listed include haemorrhage, perforations and fistulas, thromboembolic events, and hypertension and hypertensive crisis. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Cabozanib carton and leaflet. For reference, the US label for Cabometyx® describes storage at 20°C to 25°C. Keep in the original pack, out of reach of children.
Cabozanib is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Cabozanib through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Cabozanib available in India?
A.K. Pharma supplies Cabozanib (cabozantinib) 20 mg and 60 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Cabozanib contain?
Cabozantinib, an oral multi-targeted kinase inhibitor, in 20 mg and 60 mg tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Cabozanib be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
